{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:48:23Z","timestamp":1761896903488},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"31","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2019,1,2]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p> Familial hypercholesterolemia (FH) is an inherited autosomal dominant disorder that is\ncharacterized by substantially increased Low-Density Lipoprotein Cholesterol (LDL-C) levels. Patients with FH\nhave a significantly higher risk for Cardiovascular (CV) events, and the timely reduction of LDL-C is of paramount\nimportance to ameliorate the risk for CV disease. Among the available lipid-lowering therapies, the novel\nProprotein Convertase Subtilisin\/Kexin type 9 (PCSK9) inhibitors have emerged as a very promising class of\ndrugs for the management of such patients.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p> The purpose of this review is to present available data on the efficacy and safety of the two available\nPCSK9 inhibitors in patients with FH, and importantly to discuss potential differences between the two drugs.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Methods: <\/jats:title>\n<jats:p>A comprehensive literature search was performed to identify available data from clinical studies evaluating\nthe impact of evolocumab or alirocumab on lipid and CV parameters in patients with FH.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p> Several studies have assessed the lipid-lowering profile of PCSK9 inhibitors in patients with FH. Both\nevolocumab and alirocumab were found to significantly reduce LDL-C by more than 50-60% in FH patients.\nFurthermore, data also support a lower rate of lipid apheresis in FH patients receiving a PCSK9 inhibitor. In terms\nof CV outcomes, both drugs were found to possess CV-ameliorating effects of the same extent in patients with\nCV disease. However, alirocumab reduced all-cause mortality, as well, a finding not observed with evolocumab.\nSeveral differences in the study population characteristics might explain this and other mild differences observed\nin the CV trials of these drugs.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> Available evidence suggests similar potency of alirocumab and evolocumab in reducing lipids and\nCV events.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1381612824666181010124657","type":"journal-article","created":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T06:31:13Z","timestamp":1539585073000},"page":"3647-3653","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Role of PCSK9 Inhibitors in High Risk Patients with Dyslipidemia: Focus on Familial Hypercholesterolemia"],"prefix":"10.2174","volume":"24","author":[{"given":"Vasilios","family":"Papademetriou","sequence":"first","affiliation":[{"name":"VA Medical Center and Georgetown University, Washington, DC, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Stavropoulos","sequence":"additional","affiliation":[{"name":"2nd Prop Department of Internal Medicine, Aristotle University, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christodoulos","family":"Papadopoulos","sequence":"additional","affiliation":[{"name":"3rd Cardiology Department, Aristotle University, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Koutsampasopoulos","sequence":"additional","affiliation":[{"name":"2nd Prop Department of Internal Medicine, Aristotle University, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiriakos","family":"Dimitriadis","sequence":"additional","affiliation":[{"name":"1st Cardiology Department, Kapodestrian University, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kostas","family":"Tsioufis","sequence":"additional","affiliation":[{"name":"1st Cardiology Department, Kapodestrian University, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/166126","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/166126\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/166126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T19:53:30Z","timestamp":1608926010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/166126\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,2]]},"references-count":0,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2019,1,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612824666181010124657","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-08-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}